MEAK7 and cancer: Thus, mEAK-7 protein and activated mTOR signaling was found to be enhanced in primary NSCLC, and substantially detected in metastasized lymph nodes, suggesting that mEAK-7 could function as a biomarker for patients with metastasized cancers.